Effect of low-normal and high-normal IGF-1 levels on memory and wellbeing during growth hormone replacement therapy: a randomized clinical trial in adult growth hormone deficiency

What Was Tested

The paper reports a study of IGF-1 LR3, published as a randomized controlled trial.

The aim of the present study was to investigate the effect of low-normal and high-normal levels of IGF-1 in growth hormone (GH) deficient adults on cognition and wellbeing during GH treatment.

Why It Was Studied

This study is registered with ClinicalTrials.gov , number NCT01877512.

Who Took Part

According to the abstract, 32 subjects were involved.

By PubMed's age tags, the people studied were adults and middle-aged adults, both men and women.

A randomized, open-label, clinical trial including 32 subjects receiving GH therapy for at least 1 year.

Wellbeing was measured as mood by the Profile of Moods States questionnaire, and quality of life by the Nottingham Health Profile and QoL Assessment in GH Deficiency in Adults questionnaires.

How the Study Was Run

In design terms this was a randomized and open-label study.

Because people in this IGF-1 LR3 study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

Nothing was hidden in this open-label IGF-1 LR3 study: the subjects and staff both knew the treatment.

Memory was measured by the Cambridge Neuropsychological Test Automated Battery, selecting the Pattern Recognition Memory task and the Spatial Working Memory.

What Was Measured

PubMed files the paper under topics including Affect, Cognition, Growth Disorders, Hormone Replacement Therapy, Human Growth Hormone, Insulin-Like Growth Factor I and Memory.

The authors tagged it with the keywords Growth hormone deficiency, Growth hormone treatment, Insulin-like growth factor-1 and Mood.

What This Means in Plain Language

The paper is a randomized and open-label study of IGF-1 LR3 in 32 subjects.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

Results are reported in around 5 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2018 (Health and quality of life outcomes), a journal based in England.

More context: the IGF-1 LR3 compound page, all human trials.